Filtered By:
Specialty: Endocrinology
Source: Diabetes Therapy
Condition: Diabetes

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionClopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
Source: Diabetes Therapy - March 26, 2020 Category: Endocrinology Source Type: research

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
AbstractDiabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. It appears that these agents exert neuroprotective actions that might both reduce infarct size and promote recovery. The present review summarizes the evidence on the potential role of incretin-bas...
Source: Diabetes Therapy - February 6, 2019 Category: Endocrinology Source Type: research

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
ConclusionsGLP-1RAs and SGLT2is lead to similar benefits on MACE, CVD, MI, and ACD in adults with type  2 diabetes. The benefit from SGLT2is on HHF is greater than that from GLP-1RAs, while GLP-1RAs vs. placebo significantly reduce stroke whereas SGLT2is do not. The two drug classes reduce cardiovascular events independent of reductions of systolic blood pressure and body weight.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Atherosclerotic Cardiovascular Disease in Type  2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
ConclusionsASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.
Source: Diabetes Therapy - June 16, 2023 Category: Endocrinology Source Type: research

Role of Comorbidities as Limiting Factors to the Effect of Hyperbaric Oxygen in Diabetic Foot Patients: A Retrospective Analysis
Conclusions Diabetic foot patients with histories of coronary artery diseases or stroke and non-proliferative or proliferative retinopathy might resist HBOT. PAD at the femoral arterial level has been shown to have a significant negative effect on HBOT outcomes that should be first considered for surgery. In contrast, PAD below the knee does not seem to be an obstacle to the efficacy of HBOT.
Source: Diabetes Therapy - October 2, 2014 Category: Endocrinology Source Type: research

Clinical Impact of 5  Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
ConclusionIn patients prolonging treatment with liraglutide for 5  years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk.
Source: Diabetes Therapy - September 20, 2018 Category: Endocrinology Source Type: research

Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease
ConclusionThese secondary analyses suggest that broad-spectrum lifestyle interventions that focus on lowering PPG may lower the risk of future CHD, which could guide future research.Trial RegistrationClinicalTrials.gov ID: NCT02432391.
Source: Diabetes Therapy - December 18, 2018 Category: Endocrinology Source Type: research

EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China
ConclusionThe diabetes complications and comorbidities among patients with type  2 diabetes were associated with poor health utility scores, especially for those with diabetic foot, stroke, and nephropathy.
Source: Diabetes Therapy - March 8, 2020 Category: Endocrinology Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
ConclusionThe predominant impact of SGLT-2i is on “hHF or CV mortality” composite driven predominantly by reduction in hHF and not atherosclerotic CV disease.
Source: Diabetes Therapy - March 13, 2019 Category: Endocrinology Source Type: research

Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project
ConclusionThe extended SPIRITS-J study demonstrated that optimal comprehensive management in patients with type 2 diabetes according to the recent practice guidelines has succeeded in preventing macrovascular complications in Japan. This study suggests that more intensive LDL-C-lowering therapy is important for further prevention of macrovascular complications even in Japanese patients with type 2 diabetes (UMIN 000004121).
Source: Diabetes Therapy - April 25, 2019 Category: Endocrinology Source Type: research

Ten-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Patients with Type  2 Diabetes Mellitus Suffering from Left Main Coronary Disease: A Meta-Analysis
ConclusionsDuring a long-term follow-up time period of 10  years, PCI was associated with worse clinical outcomes compared to CABG in these patients with T2DM suffering from LMCD. However, a significantly higher risk of stroke was observed with CABG. This piece of information might be vital in order to carefully choose and prevent complications following revascularization in such patients.
Source: Diabetes Therapy - February 27, 2021 Category: Endocrinology Source Type: research

Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type  2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database
ConclusionsThe high incidence of CKD or HF manifestation can contribute to the augmented mortality risk in patients in the early stages of T2DM compared with patients without T2DM. These findings highlight the importance of early interventions for preventing/treating CKD and HF to improve the prognosis of patients with T2DM.
Source: Diabetes Therapy - January 10, 2022 Category: Endocrinology Source Type: research

Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
Abstract Poorly controlled diabetes is characterized by premature cardiovascular mortality and morbidity. The mechanisms linking hyperglycemia with accelerated atherosclerotic disease have not been fully elucidated; however, are thought to be mediated through vascular inflammation, oxidative stress and endothelial dysfunction. The advent of incretin-based therapy, whether by increasing endogenous glucagon-like peptide (GLP)-1 and glucose-dependent inhibitory polypeptide by inhibition of their breakdown using di-peptidyl peptidase 4 inhibitors, or augmenting GLP-1 activity using either exendin-4-based drugs or synt...
Source: Diabetes Therapy - March 23, 2016 Category: Endocrinology Source Type: research